Preview

Медицинский Совет

Расширенный поиск

СЛОЖНЫЕ ФОРМЫ ПОРАЖЕНИЙ КОРОНАРНОГО РУСЛА И ИХ ВЛИЯНИЕ НА ПРОГНОЗ

https://doi.org/10.21518/2079-701X-2017-12-196-201

Полный текст:

Аннотация

Приоритетной задачей рентгенэндоваскулярных методов лечения ишемической болезни сердца (ИБС), наряду с обеспечением эффективности и безопасности, является расширение показаний к эндоваскулярному лечению сложных форм коронарных поражений. Среди независимых предикторов неблагоприятного прогноза ЧКВ отдельный интерес представляет диффузный характер поражения КА. Значительные успехи в лечении рассматриваемой категории пациентов были получены с началом использования стентов с лекарственным покрытием. Однако оборотной стороной медали стала проблема, связанная со случаями позднего и очень позднего тромбоза стентов. С целью решения данной проблемы были разработаны стенты нового поколения с биодеградируемым полимером. Перспективным направлением является оценка эффективности и безопасности длинных стентов нового поколения в лечении диффузных и протяженных стенозов коронарных артерий.

 

 

Об авторе

Е. Н. Кононец
Российский кардиологический научно-производственный комплекс Минздрава России, Институт клинической кардиологии им. А.Л. Мясникова
Россия

аспирант

 



Список литературы

1. Puricel S, Arroyo D, Corpataux N, Baeriswyl G, Lehmann S, Kallinikou Z, et al. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. J Am Coll Cardiol. 2015 Mar 3;65(8):791-801. PubMed PMID: 25720622.

2. Polavarapu A, Polavarapu RS, Prajapati J, Thakkar K, Raheem A, Mayall T, et al. Clinical Outcomes from Unselected «Real-World» Patients with Long Coronary Lesion Receiving 40 mm Biodegradable Polymer Coated Sirolimus-Eluting Stent. Scientifica (Cairo). 2015;2015. PubMed PMID: 26579328.

3. Serruys PW, Chevalier B, Dudek D, Cequier A, Carrié D, Iniguez A, et al. A bioresorbable everoli-mus-eluting scaffold versus a metallic everoli-mus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet. 2015 Jan 3;385(9962): 43-54. PubMed PMID: 25230593.

4. Ellis SG, Vandormael MG, Cowley MJ, DiSciascio G, Deligonul U, Topol EJ, et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. Circulation. 1990 Oct; 82(4):1193-202. PubMed PMID: 2401060.

5. Тuzcu EM, Simpfendorfer C, Badhwar K, Chambers JC, Domti K, Franco J, et al. Determinants of primary success in elective PEA for significant narrowing of a single major COD nary artery. J Am Coll Cardiol. 1988; 62:873-875.

6. Madhavan MV, Tarigopula M, Mintz GS, Maehara A, Stone GW, Généreux P. Coronary artery calcification: pathogenesis and prognostic implications. J. Am. Coll. Cardiol. 2014 May 6;63(17):1703-14. PubMed PMID: 24530667.

7. Gruntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet. 1978; 1(8058):263.

8. Popma JJ, Kuntz RE, Baim DS. A decade of improvement in the clinical outcomes of percutaneous coronary intervention for multivessel coronary artery disease. Circulation. 2002 Sep 24; 106(13):1592-4. PubMed PMID: 12270845.

9. Goettsch C, Hutcheson JD, Aikawa E. MicroRNA in cardiovascular calcification: focus on targets and extracellular vesicle delivery mechanisms. Circ Res. 2013 Mar 29;112(7):1073-84.

10. Klein LW, Krone RJ. Angiographic characterization of lesion morphology. Cardiac Interventions Today. 2008. Jul/Aug: 44-49.

11. Ryan TJ, Faxon DP, Gunnar RM, Kennedy JW, King SB. Loop FD et al. Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures. Circulation. 1988;78:486-502.

12. Angeras O, Albertsson P, Karason K, Ramunddal T, Matejka G, James S, et al. Evidence for obesity paradox in patients with acute coronary syndromes: a report from the Swedish Coronary Angiography and Angioplasty Registry. Eur Heart J. 2013 Feb; 34(5):345-53. PubMed PMID: 22947610.

13. Tan K, Sulke N, Taub N, Sowton E. Clinical and lesion morphologic determinants of coronary angioplasty success and complications: current experience. J Am Coll Cardiol. 1995;25:855–865. PubMed PMID: 7884088.Krone RJ, Shaw RE, Klein LW, Block PC, Anderson HV, Weintraub WS, et al. Evaluation of the ACC/AHA and the SCAI lesion classification system in the current «stent» era of coronary interventions (from the ACC-National Cardiovascular Data Registry). Am J Cardiol. 2003; 92:389-394. PubMed. PMID: 12914867.

14. Lemos PA, Hoye A, Goedhart D, Arampatzis CA, Saia F, van der Giessen WJ, et al: Clinical, angi-ographic, and procedural predictors of angio-graphic restenosis after sirolimus-eluting stent implantation in complex patients: an evaluation from the Rapamycin-Eluting Stent Evaluated At Rot-terdam Cardiology Hospital (RESEARCH) study. Circulation. 2004 Mar 23;109(11):1366-70. PubMed PMID: 14993127.

15. Myler RK, Shaw RE, Stertzer SH, Hecht HS, Ryan C, Rosenblum J, et al. Lesion morphology and coronary angioplasty: Current experience and analysis. J Am Coll. Cardiol. 1992 Jun; 19(7):1641-52. PubMed PMID: 1593061.

16. Appelman YE, Piek JJ, Strikwerda S, Tijssen JG, de Feyter PJ, David GK, et al. Randomized trial of excimer laser angioplasty vs. balloon angioplasty for treatment of obstructive coronary artery disease. Lancet. 1996. Jan 13;347(8994):79-84. PubMed PMID: 8538345.

17. Meier B, Gruentzig AR, Hollman J, Ischinger T, Bradford JM. Does length or eccentricity of coronary stenoses influence the outcome of transluminal dilatation? Circulation. 1983; 67:497-499.

18. Savage MP, Goldberg S, Hirshfeld JW, Bass TA, MacDonald RG, Margolis JR, et al. Clinical and angiographic determinants of primary coronary angioplasty success. M-HEART investigators.J Am Coll Cardiol. 1991 Jan;17(1):22-8. PubMed PMID: 1987229.

19. Hermans WR, Foley DP, Rensing BJ, Rutsch W, Heyndrickx GR, Danchin N, et al. Usefulness of quantitative and qualitative angiographic lesion morphology, and clinical characteristics in predicting major adverse cardiac events during and after native coronary balloon angioplasty. Am J Cardiol. 1993;72:14–20. PubMed PMID: 8517422.

20. Huang Z, Chen HW, Katoh O, Nakamura S. Evaluation of long stent implantation in diffuse coronary lesions for octogenarians.J Geriatri Cardiol. 2005;2(1):29-35.

21. Tomasello SD, Giubilato S, Rubartelli P et al. TCT-190 Percutaneous Coronary Intervention Versus Medical Therapy For Coronary Chronic Total Occlusion: Result From The Italian Registry Of Chronic Total Occlusion (IRCTO). J Am Coll Cardiol. 2014; 64:65.

22. Valenti R, Migliorini A, Signorini U, Vergara R, Parodi G, Carrabba N, et al. Impact of complete revascularization with percutaneous coronary intervention on survival in patients with at least one chronic total occlusion. Eur. Heart

23. J. 2008 Oct;29(19):2336-42. PubMed PMID: 18682446.

24. Galassi AR, Tomasello SD, Reifart N, Werner GS, Sianos G, Bonnier H, et al. In-hospital outcomes of percutaneous coronary intervention in patients with chronic total occlusion: insights from the ERCTO (European Registry of Chronic Total Occlusion) registry. EuroIntervention. 2011 Aug;7(4):472-9. PubMed PMID: 21764666.

25. Lozano I, Capin E, de la Hera JM, Llosa JC, Carro A, López-Palop R. Diffuse Coronary Artery Disease Not Amenable to Revascularization: Long-term Prognosis. Rev. Esp. Cardiol. 2015;68(7):631–3. PubMed PMID: 25936615.

26. Бокерия Л.А., Алекян Б.Г., Бузиашвили Ю.И., Голухова Е.З., Никитина Т.Г., Стаферов А.В. и др. Рентгеноэндоваскулярная хирургия в лечении больных ишемической болезнью сердца с морфологически неблагоприятными формами диффузного поражения венечного русла. Грудная и серд.-сосуд. хир., 2008, 4: 30-36.

27. Xu B, Gao RL, Zhang RY, Wang HC, Li ZQ, Yang YJ, et al. Efficacy and safety of FIREHAWK abluminal groove filled biodegradable polymer sirolimus-eluting stents for the treatment of long coronary lesions: nine-month angiographic and one-year clinical results from TARGET I trial long cohort. Chin Med J (Engl). 2013 Mar; 126(6):1026-32. PubMed PMID: 23506573.

28. Di Mario C, Mara S, Flavio A, Imad S, Antonio M, Anna P, et al. Single vs multivessel treatment during primary angioplasty: results of the multicentre randomised HEpacoat for cuLPrit or multivessel stenting for Acute Myocardial Infarction (HELP AMI) Study. Int J Cardiovasc Intervent. 2004;6(3-4):128-33. PubMed PMID: 16146905.

29. Farooq V, van Klaveren D, Steyerberg EW, Meliga E, Vergouwe Y, Chieffo A,et al. Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. Lancet. 2013; 381(9867):639–50. PubMed PMID: 23439103.

30. Uddin SN, Malik F, Bari MA, Siddiqui NI, Khan GK, Rahman S, et al. Angiographic severity and extent of coronary artery disease in patients with type 2 diabetes mellitus. Mymensingh Med J. 2005 Jan;14(1):32-7. PubMed PMID: 15695951.

31. Shuhaiber JH, Evans AN, Massad MG, Geha AS. Mechanisms and future directions for prevention of vein graft failure in coronary bypass surgery. Eur J Cardiothorac Surg. 2002 Sep;22(3):387-96. PubMed PMID: 12204729.

32. Kolh P, Windecker S. ESC/EEACTS Guideline on myocardial revascularization 2014. Eur Heart J. 2014 Dec 7;35(46):3235-6. PubMed PMID: 25482397.

33. Singh M, Lennon RJ, Holmes DR Jr, Bell MR, Rihal CS. Correlates of procedural complications and a simple integer risk score for percutaneous coronary intervention. J Am Coll Cardiol. 2002; 40:387–93.

34. Singh M, Rihal CS, Lennon RJ, Garratt KN, Holmes DR Jr. Comparison of Mayo Clinic risk score and and American College of Cardiology/ American Heart Association Lesion Classification in the Prediction of Adverse Cardiovascular Outcome Following Percutaneous Coronary Interventions. J Am Coll Cardiol. 2004 Jul 21;44(2):357-61. PubMed PMID: 15261931.

35. Safian RD, Freed MS. The Manual of Interventional Cardiology. 3rd ed. Physicians Press; 2001.

36. McNeil M, Buth K, Brydie A, MacLaren A, Baskett R. The impact of diffuseness of coronary artery disease on the outcomes of patients undergoing primary and reoperative coronary artery bypass grafting. Eur J Cardiothorac Surg. 2007;31(5):827-833.

37. Wilensky RL, Selzer F, Johnston J, Laskey WK, Klugherz BD, Block P, et al. Relation of percutaneous coronary intervention of complex lesions to clinical outcomes (from the NHLBI Dynamic Registry). Am J Cardiol. 2002;90:216-221.

38. Reifart N, Schwa F, Preusler W, Starger H, Hoffmann M. Results of FTCA in more than 5000 patients without surgical standby in the same center (abstr). J Am Coll Cardiol. 1992;229:19.

39. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first generation drug-eluting stents: а cause for concern. Circulation. 2007 Mar 20;115(11):1440-55. PubMed PMID: 17344324.

40. Kamineni R, Heuser R. New Approaches to Long Lesions. J Interv Cardiol. 2004 Dec; 17(6):405-9.

41. Tenaglia AN, Zidar JP, Jackman JD Jr, Fortin DF, Krucoff MW, Tcheng JE, et al. Treatment of long coronary artery narrowings with long angioplasty balloon catheters. Am J Cardiol. 1993 Jun 1;71(15):1274-7. PubMed PMID: 8498366.

42. Dussaillant GR, Mintz GS, Pichard AD, Kent KM, Satler LF, Popma JJ, et al. Small stent size and intimal hyperplasia contribute to restenosis: a volumetric intravascular ultrasound analysis.J Am Coli Cardiol.1995; 26:720-4. PubMed PMID: 7642865.

43. Hirshfeld JW Jr, Schwartz JS, Jugo R, MacDonald RG, Goldberg S, Savage MP, et al. Restenosis after coronary angioplasty: A multivariate statistical model to relate lesion and procedure variables to restenosis. J Am Coll Cardiol. 1991;18:647-56.

44. Appleman YE, Piek J, Redekop WK, et al. Excimer laser angioplasty versus balloon angioplasty in longer coronary lesions: A multivariate analysis. Circulation. 1995;92:I-74.

45. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, et al. A randomised comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 1994 Aug 25;331(8):496-501. PubMed PMID: 8041414.

46. Sawada Y, Nosaka H, Kimura T et al. Initial and six-month outcome of Ralmaz-Schatz stent implantation: STRESS/BENESTENT equivalent versus nonequivalent lesions. J Am Coll Cardiol. 1996;27:252.

47. Serruys PW, Foley DP, Suttorp MJ, Rensing BJ, Suryapranata H, Materne P, et al. A radomized comparison of the value of additional Stenting after optimal balloon angioplasty for long coronary lesions: final results of the additional value of NIR stents for treatment of long coronary lesions (ADVANCE) study. J Am Coll Cardiol. 2002 Feb 6;39(3):393-9. PubMed PMID: 11823075.

48. Kobayashi Y, De Gregorio J, Kobayashi N, Akiyama T, Reimers B, Finci L, et al. Stented segment length as an independent predictor of restenosis. J Am Coll Cardiol. 1999; 34:651-659.

49. Kastrati A, Elezi S, Dirschinger J, Hadamitzky M, Neumann FJ, Schomig A. Influence of lesion length on restenosis after coronary stent placement. Am J Cardiol. 1999; 83: 1617-22.

50. Colombo A1, De Gregorio J, Moussa I, Kobayashi Y, Karvouni E, Di Mario C, et al. Intravascular ultrasound-guided percutaneous transluminal coronary angioplasty with provisional spot stenting for treatment of long coronary lesions. J Am Coll Cardiol. 2001; 38:1427-1433. PubMed PMID: 11691519.

51. Kereiakes DJ, Wang H, Popma JJ, Kuntz RE, Donohoe DJ, Schofer J, et al. Periprocedural and late consequences of overlapping cypher siroli-mus-eluting stents, pooled analysis of five clinical trials. J Am Coll Cardiol. 2006;48(1):21–31.

52. Roy P, Okabe T, Pinto Slottow TL, Steinberg DH, Smith K, Torguson R, et al. Correlates of clinical restenosis following intracoronary implantation of drug-eluting stents. Am J Cardiol. 2007;100:965-969. PubMed PMID: 17826379.

53. Hermiller JB, Raizner A, Cannon L, Gurbel PA, Kutcher MA, Wong SC, et al. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. J Am Coll Cardiol. 2005;45:1172-1179.

54. Lozano I, Capin E, de la Hera JM, Llosa JC, Carro A, López-Palop R. Diffuse Coronary Artery Disease Not Amenable to Revascularization: Long-term Prognosis. Rev. Esp. Cardiol. 2015; 68(7): 629–640.

55. Suh J, Park DW, Lee JY, Jung IH, Lee SW, Kim YH, et al. The relationship and threshold of stent length with regard to risk of stent thrombosis after drug-eluting stent implantation. JACC Cardiovasc Interv. 2010 Apr; 3(4):383-9. PubMed PMID: 20398864.

56. Jain RK, Chakravarthi P, Shetty R, Ramchandra P, Polavarapu RS, Wander GS, et al. One-year outcomes of a BioMime Sirolimus-Eluting Coronary Stent System with a biodegradable polymer in all-comers coronary artery disease patients: The meriT-3 study. Indian Heart J. 2016 Sep - Oct;68(5):599-603. PubMed PMID: 27773396.


Просмотров: 1826


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)